March 3, 2024

Medical Trend

Medical News and Medical Resources

Bacillus Calmette-Guerin (BCG) may have a protective effect on Alzheimer’s disease

Bacillus Calmette-Guerin (BCG) may have a protective effect on Alzheimer’s disease



 

Bacillus Calmette-Guerin (BCG) may have a protective effect on Alzheimer’s disease.


Alzheimer’s disease (AD) , commonly known as “senile dementia”, is a type of degenerative disease of the central nervous system that mainly occurs in the elderly and is characterized by progressive cognitive dysfunction and behavioral impairment. Currently, about 50 million people worldwide suffer from Alzheimer’s disease.

As the average life expectancy of human beings increases and the aging society intensifies, the prevalence of Alzheimer’s disease is also increasing. It is estimated that by 2050, the number of patients with Alzheimer’s disease will increase to more than 150 million.

 

Bacillus Calmette-Guerin (BCG) , a live bacterial vaccine made from a suspension of attenuated Mycobacterium bovis, is used to prevent tuberculosis .

And it also has the ability to enhance the activity of macrophages and kill tumor cells, activate T lymphocytes, and enhance the body’s cellular immunity.

It is also currently recommended for the treatment of non-muscle invasive bladder cancer.

 

A new study from Harvard Medical School shows that treatment with BCG is associated with a reduced risk of Alzheimer’s disease and related dementias.

The study was published in JAMA Network Open under the title : Association of BCG Vaccine Treatment With Death and Dementia in Patients With Non–Muscle-Invasive Bladder Cancer .

 

Bacillus Calmette-Guerin (BCG) may have a protective effect on Alzheimer's disease

 

Although previous studies have shown a link between BCG and a reduced risk of dementia, these studies were limited by size, study design, or analysis methods.

In order to conduct a more convincing study, the research team followed up 6,467 patients diagnosed with non- muscle-invasive bladder cancer for up to 15 years, of which 3,388 patients received BCG treatment, and the other 3,079 patients served as controls groups and were matched based on factors such as age, sex, and comorbidities .

 

During the follow-up period, 202 patients in the BCG-treated group and 262 in the control group developed Alzheimer’s disease and related dementias.

The incidence rates of the two groups were 8.8/1000 person-year and 12.1/1000 person-year respectively. The analysis showed that treatment with BCG was associated with a 20 percent lower risk of Alzheimer’s disease and related dementias .

This protective association was greater in patients aged 70 years and older.

In addition, during follow-up, there were 751 deaths in the BCG-treated group compared with 973 in the control group, and BCG treatment was associated with a 25% reduction in the risk of death.

 

Bacillus Calmette-Guerin (BCG) may have a protective effect on Alzheimer's disease

 

 

A vaccine like BCG, if proven effective, would be a perfect example of a cost-effective, population health-based solution to a devastating disease like Alzheimer’s, the research team said.

The research team is shifting their focus to studying the potential benefits of BCG vaccination in older adults in clinical trials related to Alzheimer’s disease.

 

This study is the discovery of an association between BCG treatment and a reduced risk of Alzheimer’s disease. If you want to further causal relationships, it is crucial to find out the mechanism of action.

The research team said that BCG’s impact on the immune system may play a protective role. effect.

 

 

 

 

Paper link :
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805030

Bacillus Calmette-Guerin (BCG) may have a protective effect on Alzheimer’s disease

(source:internet, reference only)


Disclaimer of medicaltrend.org


Important Note: The information provided is for informational purposes only and should not be considered as medical advice.